Stephen Berenson - Apr 28, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Director
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Apr 28, 2022
Transactions value $: $0
Form type: 4
Date filed: 5/2/2022, 04:47 PM
Previous filing: Aug 20, 2021
Next filing: Jun 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+703	+3.5%	$0.00	20.8K	Apr 28, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-703	-100%	$0.00^*	0	Apr 28, 2022	Common Stock	703	$0.00	Direct	F1, F2
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+4.06K		$0.00	4.06K	Apr 28, 2022	Common Stock	4.06K	$142.52	Direct	F3
transaction	MRNA	Restricted Stock Units	Award	$0	+670		$0.00	670	Apr 28, 2022	Common Stock	670	$0.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	The shares subject to this restricted stock unit award vested in full on April 28, 2022.
F3	This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F4	The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.